| Code | Description | Claims | Beneficiaries | Total Paid |
|---|
| 90999 |
|
35,336 |
2,500 |
$1.42M |
| Q4081 |
Injection, epoetin alfa, 100 units (for esrd on dialysis) |
37,326 |
1,929 |
$597K |
| J1756 |
Injection, iron sucrose, 1 mg |
7,769 |
1,664 |
$38K |
| J0887 |
Injection, epoetin beta, 1 microgram, (for esrd on dialysis) |
530 |
193 |
$26K |
| 83970 |
|
1,309 |
982 |
$14K |
| J1270 |
Injection, doxercalciferol, 1 mcg |
15,842 |
1,237 |
$6K |
| 82108 |
|
549 |
415 |
$3K |
| A4657 |
Syringe, with or without needle, each |
2,053 |
1,658 |
$3K |
| 83550 |
|
659 |
502 |
$1K |
| 82728 |
|
709 |
542 |
$1K |
| 85045 |
|
1,255 |
1,010 |
$1K |
| 85041 |
|
1,475 |
1,191 |
$1K |
| 83540 |
|
762 |
570 |
$1K |
| 85048 |
|
1,472 |
1,190 |
$1K |
| 82607 |
|
62 |
57 |
$150.72 |
| 82746 |
|
47 |
42 |
$72.30 |
| G0499 |
Hepatitis b screening in non-pregnant, high risk individual includes hepatitis b surface antigen (hbsag), antibodies to hbsag (anti-hbs) and antibodies to hepatitis b core antigen (anti-hbc), and is followed by a neutralizing confirmatory test, when performed, only for an initially reactive hbsag result |
633 |
307 |
$0.00 |
| 90674 |
|
14 |
13 |
$0.00 |